1
Clinical Trials associated with NY-ESO-1 TCR redirected autologous T cell product(Centre Hospitalier Universitaire Vaudois)A Phase I Study Evaluating Safety and Feasibility of Redirected Autologous T Cells Expressing a High Affinity TCR Specific for NY-ESO-1 (LauT-1) in Patients With Advanced Melanoma and Sarcoma
A single center, Phase I clinical trial to demonstrate safety and efficacy of LauT-1, autologous "New York Esophageal Squamous Cell Carcinoma-1 T-Cell Receptor (NY-ESO-1 TCR)-directed T cells in combination with non-myeloablative (NMA) lymphodepleting chemotherapy and low dose irradiation (LDI) in patients with NY-ESO-1 positive sarcoma and melanoma.
100 Clinical Results associated with NY-ESO-1 TCR redirected autologous T cell product(Centre Hospitalier Universitaire Vaudois)
100 Translational Medicine associated with NY-ESO-1 TCR redirected autologous T cell product(Centre Hospitalier Universitaire Vaudois)
100 Patents (Medical) associated with NY-ESO-1 TCR redirected autologous T cell product(Centre Hospitalier Universitaire Vaudois)
100 Deals associated with NY-ESO-1 TCR redirected autologous T cell product(Centre Hospitalier Universitaire Vaudois)